Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM.

Cancer Immunol Immunother. 2017 Jul;66(7):891-901. doi: 10.1007/s00262-017-1994-y. Epub 2017 Apr 8.

PMID:
28391357
2.

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R.

Clin Nutr. 2017 Jun;36(3):672-679. doi: 10.1016/j.clnu.2016.06.014. Epub 2016 Jun 30.

3.

Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.

Lilleby W, Stensvold A, Dahl AA.

Acta Oncol. 2016 Jul;55(7):807-13. doi: 10.3109/0284186X.2015.1127417. Epub 2016 Mar 9.

PMID:
26959297
4.

Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report.

Lilleby W, Vlatkovic L, Meza-Zepeda LA, Revheim ME, Hovig E.

J Med Case Rep. 2015 Dec 9;9:281. doi: 10.1186/s13256-015-0749-7.

5.

Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.

Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K.

Radiat Oncol. 2015 Nov 17;10:232. doi: 10.1186/s13014-015-0540-3.

6.

[Re: Different guidelines for treatment of prostate cancer].

Solberg A, Angelsen A, Berge V, Lilleby W, Iversen J, Klepp O, Brennhovd B, Johannessen D, Nygård Y, Larsen K, Stensvold A.

Tidsskr Nor Laegeforen. 2015 Jun 30;135(12-13):1105. doi: 10.4045/tidsskr.15.0652. eCollection 2015 Jun 30. Norwegian. No abstract available.

7.

[Re: The problematical prostate cancer].

Lilleby W, Raabe NK, Normann M.

Tidsskr Nor Laegeforen. 2015 Jun 16;135(11):1009. doi: 10.4045/tidsskr.15.0593. eCollection 2015 Jun 16. Norwegian. No abstract available.

8.

Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.

Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L.

Acta Oncol. 2015 Nov;54(10):1805-13. doi: 10.3109/0284186X.2015.1037008. Epub 2015 Apr 30.

PMID:
25927504
9.

Low-dose-rate brachytherapy for low-grade prostate cancer.

Raabe NK, Normann M, Lilleby W.

Tidsskr Nor Laegeforen. 2015 Mar 24;135(6):548-52. doi: 10.4045/tidsskr.13.1404. eCollection 2015 Mar 24. Review. English, Norwegian.

10.

Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.

Lilleby W, Stensvold A, Dahl AA.

Acta Oncol. 2014 Oct;53(10):1380-9. doi: 10.3109/0284186X.2014.916042. Epub 2014 May 20.

PMID:
24844918
11.

Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10.

PMID:
24035332
12.
13.

Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients.

Lilleby W, Stensvold A, Mills IG, Nesland JM.

Int J Cancer. 2013 Jul;133(1):149-55. doi: 10.1002/ijc.28002. Epub 2013 Jan 24.

14.

Bother problems in prostate cancer patients after curative treatment.

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S.

Urol Oncol. 2013 Oct;31(7):1067-78. doi: 10.1016/j.urolonc.2011.12.020. Epub 2012 Feb 16.

PMID:
22341412
15.

Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.

Lilleby W, Tafjord G, Raabe NK.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):933-9. doi: 10.1016/j.ijrobp.2011.08.028. Epub 2011 Dec 2.

PMID:
22138456
16.

Detection of prostate cancer relapse with PET/CT using a novel radiotracer.

Lilleby W, Willoch F, Stensvold A.

Acta Oncol. 2012 Mar;51(3):397-9. doi: 10.3109/0284186X.2011.614638. Epub 2011 Sep 22. No abstract available.

PMID:
21936756
17.

Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones.

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S.

Prostate. 2012 May 1;72(6):668-76. doi: 10.1002/pros.21470. Epub 2011 Aug 1.

PMID:
21809351
18.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group.

Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.

PMID:
21803569
19.

Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.

Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W.

Clin Oncol (R Coll Radiol). 2011 Jun;23(5):339-43. doi: 10.1016/j.clon.2010.11.006. Epub 2010 Dec 4.

PMID:
21134733
20.

Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center.

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S.

Acta Oncol. 2011 Apr;50(3):408-14. doi: 10.3109/0284186X.2010.492236. Epub 2010 Jun 30.

PMID:
20586661

Supplemental Content

Loading ...
Support Center